The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that ...

The UK announced the funding at the AI Action Summit in Paris where it abstained from signing a declaration on an inclusive ...

The World Health Organization and St Jude Children's Research Hospital have kicked off a programme to distribute cancer ...

Grace has announced the initial closing of a financing round, securing almost $15m, for funding pre-commercial development of ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...